Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293,061,432
-
Total 13F shares
-
122,700,757
-
Share change
-
-6,075,096
-
Total reported value
-
$795,296,987
-
Put/Call ratio
-
65%
-
Price per share
-
$6.46
-
Number of holders
-
163
-
Value change
-
-$50,606,062
-
Number of buys
-
74
-
Number of sells
-
96
Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q2 2023
As of 30 Jun 2023,
AbCellera Biologics Inc. - Ordinary Shares (ABCL) was held by
163 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
122,700,757 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, BAKER BROS. ADVISORS LP, Voya Investment Management LLC, Capital World Investors, CREDIT SUISSE AG/, ORBIMED ADVISORS LLC, ArrowMark Colorado Holdings LLC, Founders Fund VII Management, LLC, BlackRock Inc., and FEDERATED HERMES, INC..
This page lists
166
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.